| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| Targets |
ERK1; ERK2
|
|---|---|
| ln Vitro |
ASTX029 (96 h) has IC50 values ranging from 1.8 to 380 nM, which means that it suppresses the phosphorylation of human cancer cells with mutations that activate MAPK [2]. With IC50 values of 3.3 for A375 and HCT116 cells, respectively, ASTX029 (2 h) suppresses RSK phosphorylation. In A375 and HCT116 cells, ASTX029 (10 and 100 nM, 0-72 h) causes cell life cycle candles in the G1 phase and induces transplanting [2].
|
| ln Vivo |
In tumor-bearing Colo205 (BRAFV600E-mottled colorectal cancer) tumors, ASTX029 (20–75 mg/kg, neck) inhibits tumor growth [2]. T1/2 was 2.9 hours, F (%) was 42%, and AUC for ASTX029 (5 mg/kg, neck, neck) was 1600 ng h/mL [3].
|
| Cell Assay |
Western Blot Analysis[2]
Cell Types: A375 and HCT116 Cell Tested Concentrations: 1 nM-100 nM Incubation Duration: 2 hrs (hours) Experimental Results: pRSK and pERK diminished. Apoptosis analysis[2] Cell Types: A375 and HCT116 Cell Tested Concentrations: 0-100 nM Incubation Duration: 0-72 hrs (hours) Experimental Results: Cell arrest in G1 phase. Cleaved PARP and Bim protein levels increased. |
| Animal Protocol |
Animal/Disease Models: Colo205, A375, Calu-6, HCC44, HCT116 or MA-MEL-28 xenograft tumors in mice [2]
Doses: 75 mg/kg Route of Administration: po (po (oral gavage)) one time/day Experimental Results: In multiple tumor models Inhibit tumor growth. |
| References |
[1]. Michael Reader, et al. 6-pyrimidin-isoindole derivative as erk1/2 inhibitor. WO2018193410A1.
[2]. Munck JM, et al. ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK. Mol Cancer Ther. 2021 Oct;20(10):1757-1768. |
| Molecular Formula |
C29H31CLFN5O5
|
|---|---|
| Molecular Weight |
584.0454
|
| Exact Mass |
583.20
|
| Elemental Analysis |
C, 59.64; H, 5.35; Cl, 6.07; F, 3.25; N, 11.99; O, 13.70
|
| CAS # |
2095719-92-7
|
| Related CAS # |
2095719-92-7
|
| Appearance |
Solid powder
|
| SMILES |
C[C@H](C(=O)N[C@H](CO)C1=CC(=CC(=C1)F)OC)N2CC3=C(C2=O)C=C(C=C3)C4=NC(=NC=C4Cl)NC5CCOCC5
|
| InChi Key |
BVRGQPJKSKKGIH-PUAOIOHZSA-N
|
| InChi Code |
InChI=1S/C29H31ClFN5O5/c1-16(27(38)34-25(15-37)19-9-20(31)12-22(10-19)40-2)36-14-18-4-3-17(11-23(18)28(36)39)26-24(30)13-32-29(35-26)33-21-5-7-41-8-6-21/h3-4,9-13,16,21,25,37H,5-8,14-15H2,1-2H3,(H,34,38)(H,32,33,35)/t16-,25-/m1/s1
|
| Chemical Name |
(2R)-2-[5-[5-chloro-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxo-1H-isoindol-2-yl]-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide
|
| Synonyms |
ASTX-029; ASTX029; ASTX 029
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100~250 mg/mL (171.2~428.1 mM)
Ethanol: ~50 mg/mL (~85.6 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (3.56 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7122 mL | 8.5609 mL | 17.1218 mL | |
| 5 mM | 0.3424 mL | 1.7122 mL | 3.4244 mL | |
| 10 mM | 0.1712 mL | 0.8561 mL | 1.7122 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
